Dyne Therapeutics (DYN) Insider Dirk Kersten Sells $3.9M of Stock

On June 22, 2026, Dirk Kersten sold 190,676 shares of Dyne Therapeutics, Inc. (NasdaqGS: DYN) in a planned transaction. This sale was valued at approximately $3.92 million, with shares sold at an average price of $20.57 each.

Insider Buying and Selling at Dyne Therapeutics, Inc.

Dirk Kersten has been active in trading Dyne Therapeutics shares recently. On June 23, he sold another 73,286 shares at an average price of $21.05, and earlier in the month, he sold 46,901 shares on June 18 and 37,454 shares on June 17. Each of these transactions was part of a planned series of sales. Meanwhile, Barry Greene purchased 57,463 shares on June 22.

Other Institutional Activity in Dyne Therapeutics

T. Rowe Price Investment Management, Inc. grew its holdings by 13,245,712 shares, ending with 30,785,801 shares worth about $558.15 million. Janus Henderson Group PLC trimmed its position by 240,346 shares, resulting in 13,647,376 shares valued at $247.43 million. BlackRock, Inc. added 509,032 shares, bringing its total to 11,699,870 shares worth approximately $212.12 million. Atlas Venture Life Science Advisors, LLC maintained its position with 9,130,465 shares valued at $165.54 million. FMR LLC increased its stake by 2,339,059 shares, totaling 8,908,980 shares worth about $161.52 million.

Dyne Therapeutics, Inc. Stock Up 18.4%

Shares of Dyne Therapeutics traded near $20.26 on Thursday. The company has a market cap of around $3.45 billion and a forward P/E ratio that isn't meaningful due to its current lack of profitability. With a beta of 1.083, the stock has experienced a 52-week low of $8.06 and a high of $25.00. Its 50-day moving average is $18.29, while the 200-day moving average stands at $17.67. Dyne maintains a strong balance sheet with a current ratio of 19.92 and a quick ratio of 18.97.

Analysts Set New Price Targets

On May 15, 2026, Evercore ISI Group maintained a buy rating with a $33.00 price target. Bernstein kept a hold rating with a $24.00 target on May 13, 2026. The consensus among analysts is a strong buy, with an average target price of $38.25, based on 16 opinions.

About Dyne Therapeutics

Dyne Therapeutics, Inc. is a biotechnology company focused on developing treatments for neuromuscular diseases. Based in Waltham, Massachusetts, the company is working on a range of therapies for muscle diseases, including myotonic dystrophy type 1, Duchenne muscular dystrophy, and Pompe disease. Led by CEO Mr. John G. Cox, Dyne leverages its FORCE platform to deliver potential disease-modifying therapies. The company employs 263 people and was founded in 2017.

Bottom Line

Dirk Kersten's recent planned sales of Dyne Therapeutics shares highlight insider activity at the company. With a strong market position and a promising pipeline of treatments, Dyne remains a focus for investors. Analysts' strong buy consensus and high target prices reflect optimism about the company's potential, although these insights are based on past data and may not indicate current positions.